Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients

To evaluate the efficacy and safety of chidamide combined with brentuximab vedotin regimen for CD30 positive PTCL patients who are unfit for chemotherapy.

Trial Details

NCT ID
NCT07074457
Phase
NA
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
  • Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide)
  • Maintenance therapy-chidamide
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Age ≥70 years or age \< 70 years and unfit for chemotherapy, male or female not limited;
  • Patients must have the capacity to understand and willingly provide written informed consent;
  • ECOG score 0-3 points;
  • Expected lifespan\>3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →